Kvetiapin Pharmas (Quetiapine)

Quetiapine works by blocking serotonin 5‑HT2A and dopamine D2 receptors while partially stimulating 5‑HT1A receptors. This combined antagonism and partial agonism balances neurotransmitter activity in brain circuits that control mood, perception and cognition, thereby reducing psychotic and mood‑related symptoms.

The appropriate dose of Kvetiapin Pharmas is individualized by the prescribing clinician based on the specific diagnosis, severity of symptoms, patient age, metabolic status and any concomitant medications. Dosage titration follows clinical guidelines and patient response.

Safety data for quetiapine in pregnancy and lactation are limited. It should only be used when the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Kvetiapin Pharmas, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other atypical antipsychotics, quetiapine has a relatively lower affinity for dopamine D2 receptors and higher antihistaminic activity, which often results in pronounced sedation and weight gain. Its broad receptor profile can be advantageous for mood‑stabilising effects, but individual response and side‑effect tolerance vary.

Kvetiapin Pharmas tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Kvetiapin Pharmas is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, and severe orthostatic hypotension. Patients should be monitored for fever, muscle rigidity, involuntary movements, sudden drops in blood pressure, or any new cardiac or metabolic abnormalities, and report these promptly.

Kvetiapin Pharmas is contraindicated in individuals with known hypersensitivity to quetiapine or any of its excipients. Caution is also advised for patients with uncontrolled cardiovascular disease, severe hepatic impairment, or those taking medications that strongly induce or inhibit CYP3A4 without appropriate monitoring.